Oncolytics Biotech Inc.

Toronto Stock Exchange ONC.TO

Oncolytics Biotech Inc. EBITDA Margin for the year ending December 31, 2023

Oncolytics Biotech Inc. EBITDA Margin is NA for the year ending December 31, 2023. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
SV Wall Street
Toronto Stock Exchange: ONC.TO

Oncolytics Biotech Inc.

CEO Mr. Wayne F. Pisano M.B.A.
IPO Date June 1, 2000
Location Canada
Headquarters 322 11th Avenue SW
Employees 29
Sector Healthcare
Industries
Biotechnology Cosmetics Pharmaceuticals Vaccines
Description

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Similar companies

TH.TO

Theratechnologies Inc.

USD 1.52

2.02%

StockViz Staff

February 7, 2025

Any question? Send us an email